MdxHealth (TM) : MDxHealth Completes €18 Million ($24M) Equity Raise

     MdxHealth (TM) : MDxHealth Completes €18 Million ($24M) Equity Raise

LIEGE, BELGIUM - June 25, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading
molecular diagnostics  company  that develops  and  commercializes  epigenetic 
tests to support  the diagnosis  and treatment of  cancer patients,  announced 
today that it  successfully raised  an aggregate amount  of €18  million in  a 
private  placement  through  the  issuance  of  8,737,683  new  shares  at   a 
subscription price of EUR 2.06 per share (which represents the average closing
price of the company's shares during the 30 preceding calendar days).  Certain 
funds managed by  Valiance Asset  Management Ltd participated  in the  private 
placement for a total amount of 4,368,932 new shares and Biovest Comm. VA, the
investment company of Rudi Mariën, participated in the private placement for a
total amount of 2,427,184 new shares. The remaining 1,941,747 new shares  were 
underwritten by Petercam who  acted as sole lead  manager in the  transaction, 
and will be placed with a limited group of investors.

The net proceeds of the private placement will be used to support and scale-up
the Company's U.S.-based CLIA-registered  commercial laboratory, its  US-based 
sales and marketing efforts,  European and global  commercial efforts for  its 
Clinical  Molecular   Diagnostics   (ClinicalMDx)   and   Pharmaco   Molecular 
Diagnostics  (PharmacoMDx)   solutions   and  services   to   clinicians   and 
pharmaceutical customers, and to accelerate proprietary product development.

The 1,941,747 new shares underwritten by  Petercam with the view to be  placed 
with investors  are  expected to  be  admitted  to listing  on  NYSE  Euronext 
Brussels immediately  following  their issuance.  The  other new  shares  are 
expected  to  be  listed  in  the  near  future  following  the  approval  and 
publication of a listing prospectus.

"This financing  marks a  major milestone  in the  growth and  success of  our 
Company," stated  Dr.  Jan  Groen,  CEO of  MDxHealth.  "In  response  to  the 
increasing demand for our ConfirmMDx^TM for Prostate Cancer test in the  U.S., 
we  will  expand  our  commercial  efforts  by  investing  in  personnel   and 
infrastructure to ensure we  are well positioned for  new tests emerging  from 
our product pipeline.   We will  also use proceeds  to further emphasize  our 
global commercialization  efforts,  offering  our cutting  edge  products  and 
services  to  clinical  and  pharmaceutical   customers,  with  the  goal   of 
accelerating and diversifying our revenue base."

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  Company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain and lung cancers. The company is based in Irvine,
California  with  a  European  headquarters   in  Liege,  Belgium.  For   more 
information visit MDxHealth's website at

For more information: Mike Sinclair          Seth Lewis
Dr. Jan Groen, CEO    Halsin Partners        The Trout Group
MDxHealth             UK: +44 20 7318 2955
US: +1 949 812 6979   Cell: +44 7968 022075  US: +1 646 378 2952
BE: +32 4 364 20 70 

Important notice

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.